Streetbeat News

INVVY

Indivior Plc

http://indivior.com/

CEO

Shaun Thaxter

Industry

Medicinal and Botanical Manufacturing

Open

21.65

Mkt cap

Volume

8.1K

High

21.85

P/E Ratio

-62.42

52-wk high

75.65

Low

21.85

Div yield

N/A

52-wk low

14.76

Indivior PLC's subsidiary, Indivior Inc., has reached a $102.5 million settlement to resolve antitrust litigation claims brought by 41 states and the District of Columbia. The settlement will be recorded against the $290 million provision and is expected to be paid in June 2023.

Portfolio Pulse from Vuk Zdinjak

June 05, 2023 | 12:14 pm

TCS Capital Management has built a stake in Yelp and urged the company to explore strategic alternatives, including a sale. Micron Technology projects the recent China ban on memory chip sales to curb revenues. Spruce Point Capital raises concerns about Perion Network's financial practices.

Portfolio Pulse from Vandana Singh

May 23, 2023 | 1:49 pm

The FDA has approved Indivior's Opvee nasal spray for emergency treatment of opioid overdose in adults and pediatric patients aged 12 years and older. Indivior acquired the product from Opiant Pharmaceuticals and expects annual net revenue of $150 million to $250 million from Opvee.

Portfolio Pulse from Vandana Singh

May 23, 2023 | 11:16 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.